January 9, 2023 – Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-c...
January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...
(30 December 2022, Hong Kong, China)Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stock...
November 21, 2022 - Luye Pharma Group announced today that a pivotal study conducted in the U.S. for the company's in-house developed innovative formulation, Paliperidone Palmitate Extended-releas...
Luye Pharma Group today announced that Denosumab Injection (Boyoubei®) developed by its subsidiary Boan Biotech has been approved for launch in China by the National Medical Products Administration (N...
November 3, 2022 – Luye Pharma Group today announced that Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its innovative drug for treating Major Depressive Disorder (MDD)...
October 27, 2022 -- Luye Pharma Group announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This...
On September 13, 2022, Luye Life Sciences Group and the Ministry of Innovative Development of the Republic of Uzbekistan signed a Memorandum of Understanding (MoU) for strategic collaboration on the U...
Shanghai, September 12, 2022 – BA-CovMab injection, the broad-spectrum neutralizing antibody developed by Luye Pharma Group subsidiary Boan Biotech for use against severe acute respiratory syndr...
Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...
TOP